Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (54) 54
life sciences & biomedicine (51) 51
humans (42) 42
male (24) 24
female (23) 23
hematology (23) 23
middle aged (23) 23
oncology (21) 21
antineoplastic combined chemotherapy protocols - therapeutic use (19) 19
aged (18) 18
adult (14) 14
animals (13) 13
biological and medical sciences (12) 12
medical sciences (12) 12
aged, 80 and over (9) 9
chemotherapy (9) 9
rituximab (9) 9
social sciences (9) 9
treatment outcome (9) 9
disease-free survival (8) 8
environmental sciences & ecology (8) 8
hematologic and hematopoietic diseases (8) 8
hemic and lymphatic diseases (8) 8
leukemias. malignant lymphomas. malignant reticulosis. myelofibrosis (8) 8
lymphoma, large b-cell, diffuse - drug therapy (8) 8
research (8) 8
abridged index medicus (7) 7
antibodies, monoclonal - administration & dosage (7) 7
cancer (7) 7
mantle cell lymphoma (7) 7
mice (7) 7
non-hodgkin lymphoma (7) 7
apoptosis - drug effects (6) 6
business & economics (6) 6
care and treatment (6) 6
cell line, tumor (6) 6
combined modality therapy (6) 6
economics (6) 6
environmental sciences (6) 6
lymphoma (6) 6
lymphoma, b-cell - drug therapy (6) 6
lymphomas (6) 6
public, environmental & occupational health (6) 6
survival analysis (6) 6
young adult (6) 6
analysis (5) 5
antibodies, monoclonal, murine-derived - therapeutic use (5) 5
antineoplastic agents (5) 5
apoptosis (5) 5
follicular lymphoma (5) 5
immune system diseases (5) 5
lymphocytes b (5) 5
lymphoma, large b-cell, diffuse - pathology (5) 5
lymphoma, mantle-cell - drug therapy (5) 5
neoplasm staging (5) 5
non-hodgkin's lymphomas (5) 5
prognosis (5) 5
tumors (5) 5
xenograft model antitumor assays (5) 5
adolescent (4) 4
antibodies, monoclonal - therapeutic use (4) 4
antineoplastic agents - pharmacology (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
aurora kinases (4) 4
cell proliferation (4) 4
cell proliferation - drug effects (4) 4
diabetes (4) 4
diabetes mellitus - epidemiology (4) 4
diffuse large b-cell lymphoma (4) 4
economic development (4) 4
economic models (4) 4
employment (4) 4
health aspects (4) 4
job creation (4) 4
lymphoma, b-cell - pathology (4) 4
lymphoma, follicular - mortality (4) 4
lymphoma, large b-cell, diffuse - metabolism (4) 4
lymphoma, non-hodgkin - drug therapy (4) 4
lymphoma, non-hodgkin - pathology (4) 4
mice, scid (4) 4
pcb (4) 4
polychlorinated biphenyls - blood (4) 4
protein-serine-threonine kinases - antagonists & inhibitors (4) 4
pyrimidines - pharmacology (4) 4
recurrence (4) 4
studies (4) 4
vincristine - administration & dosage (4) 4
antibodies, monoclonal, murine-derived (3) 3
antimitotic agents (3) 3
antineoplastic agents - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
aurora kinase b (3) 3
azepines - pharmacology (3) 3
clinical trials (3) 3
cohort studies (3) 3
cyclophosphamide - administration & dosage (3) 3
disease progression (3) 3
docetaxel (3) 3
doxorubicin - administration & dosage (3) 3
economic theory (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Limited-stage DLBCL: It's patient selection
by Persky, Daniel O
Blood, ISSN 0006-4971, 01/2018, Volume 131, Issue 2, pp. 155 - 156
Life Sciences & Biomedicine | Hematology | Science & Technology | Index Medicus | Abridged Index Medicus | 29
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies
by Danilov, Alexey V and Persky, Daniel O
British journal of haematology, ISSN 0007-1048, 11/2020
Life Sciences & Biomedicine | Hematology | Science & Technology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma
by Qi, Wenqing and Cooke, Laurence S and Liu, Xiaobing and Rimsza, Lisa and Roe, Denise J and Persky, Ann Manziolli. Daniel O and Miller, Thomas P and Mahadevan, Daruka
Biochemical pharmacology, ISSN 0006-2952, 2011, Volume 81, Issue 7, pp. 881 - 890
MLN8237 | Aurora A and B | Mantle cell lymphoma (MCL) | Aurora Inhibitor | Non-Hodgkin lymphoma (NHL) | Docetaxel | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Pharmacology. Drug treatments | Taxoids - pharmacology | Apoptosis - drug effects | Pyrimidines - administration & dosage | Humans | Lymphoma, Mantle-Cell - pathology | Aurora Kinases | Pyrimidines - pharmacology | Mice, SCID | Aurora Kinase A | Azepines - pharmacology | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Animals | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cell Line, Tumor | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Azepines - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Treatment of Early (Limited)-Stage DLBCL
by Kumar, Abhijeet and Persky, Daniel O
Clinical lymphoma, myeloma and leukemia, ISSN 2152-2650, 09/2020, Volume 20, pp. S34 - S36
Limited stage | DLBCL | tiuxetan | ibritumomab | PET | Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1
by Li, L and Pongtornpipat, P and Tiutan, T and Kendrick, S.L and Park, S and Persky, D.O and Rimsza, L.M and Puvvada, S.D and Schatz, J.H
Leukemia, ISSN 0887-6924, 08/2015, Volume 29, Issue 8, pp. 1702 - 1712
Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Apoptosis - drug effects | Tissue Array Analysis | Humans | Myeloid Cell Leukemia Sequence 1 Protein - metabolism | Lymphoma, Large B-Cell, Diffuse - metabolism | Immunoenzyme Techniques | Proto-Oncogene Proteins c-bcl-2 - metabolism | Female | Tumor Cells, Cultured | Real-Time Polymerase Chain Reaction | Myeloid Cell Leukemia Sequence 1 Protein - antagonists & inhibitors | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - pathology | RNA, Messenger - genetics | Antineoplastic Combined Chemotherapy Protocols | Mice, SCID | Reverse Transcriptase Polymerase Chain Reaction | Sulfonamides - pharmacology | Myeloid Cell Leukemia Sequence 1 Protein - genetics | Drug Synergism | Lymphoma, Large B-Cell, Diffuse - mortality | Xenograft Model Antitumor Assays | Pyridinium Compounds - pharmacology | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Animals | Mice, Inbred NOD | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Cell Proliferation - drug effects | Mice | Proto-Oncogene Proteins c-bcl-2 - genetics | Proteins | Chemical inhibitors | Leukemia research | Dosage and administration | Research | Non-Hodgkin's lymphomas | Drug therapy | Health aspects | Apoptosis | Drugs | Animal models | Risk groups | Cyclin-dependent kinases | Xenotransplantation | Risk | Myc protein | Kinases | Lymphoma | Patients | Mcl-1 protein | Anticancer properties | Cyclin-dependent kinase | Chemotherapy | Lymphocytes B | Xenografts | Antitumor activity | Inhibition | B-cell lymphoma | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Phase II Study of Rituximab Plus Three Cycles of CHOP and Involved-Field Radiotherapy for Patients With Limited-Stage Aggressive B-Cell Lymphoma: Southwest Oncology Group Study 0014
by Daniel O. Persky and Joseph M. Unger and Catherine M. Spier and Baldassarre Stea and Michael LeBlanc and Matthew J. McCarty and Lisa M. Rimsza and Richard I. Fisher and Thomas P. Miller and Southwest Oncology Group
Journal of clinical oncology, ISSN 0732-183X, 05/2008, Volume 26, Issue 14, pp. 2258 - 2263
Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lymphoma, B-Cell - radiotherapy | Male | Cyclophosphamide - adverse effects | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Lymphoma, B-Cell - drug therapy | Prednisone - administration & dosage | Antibodies, Monoclonal, Murine-Derived | Prednisone - adverse effects | Rituximab | Combined Modality Therapy | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, B-Cell - pathology | Vincristine - adverse effects | Aged | Neoplasm Staging | Doxorubicin - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text A phase I/II trial of vorinostat (SAHA) in combination with rituximab‐CHOP in patients with newly diagnosed advanced stage diffuse large B‐cell lymphoma (DLBCL): SWOG S0806
by Persky, Daniel O and Li, Hongli and Rimsza, Lisa M and Barr, Paul M and Popplewell, Leslie L and Bane, Charles L and Von Gehr, Ann and LeBlanc, Michael and Fisher, Richard I and Smith, Sonali M and Friedberg, Jonathan W
American journal of hematology, ISSN 0361-8609, 04/2018, Volume 93, Issue 4, pp. 486 - 493
Life Sciences & Biomedicine | Hematology | Science & Technology | Antimitotic agents | Broadway theater | Care and treatment | Chemotherapy | Lymphomas | Product development | Antineoplastic agents | Cancer | Histone deacetylase | Chromatin | Statistical analysis | Cell survival | Transcription | Toxicity | Rituximab | Lymphoma | Hypotheses | Lymphocytes B | Sepsis | Acetylation | Histocompatibility | Neutropenia | Index Medicus | vorinostat | histone deacetylase inhibitor | diffuse large B-cell lymphoma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone
by Daniel O. Persky and David Dornan and Bryan H. Goldman and Rita M. Braziel and Richard I. Fisher and Michael LeBlanc and David G. Maloney and Oliver W. Press and Thomas P. Miller and Lisa M. Rimsza
Haematologica (Roma), ISSN 0390-6078, 06/2012, Volume 97, Issue 6, pp. 937 - 942
Combined monoclonal antibody | FCGR | Follicular lymphoma | Chemotherapy | SWOG | Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Lymphoma, Follicular - therapy | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Lymphoma, Follicular - diagnosis | Lymphoma, Follicular - mortality | Rituximab | Antibodies, Monoclonal - therapeutic use | Genotype | Male | Receptors, IgG - genetics | Lymphoma, Follicular - immunology | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Adult | Female | Aged | Combined Modality Therapy - methods | Polymorphism, Single Nucleotide | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Index Medicus | Original and Brief Reports | follicular lymphoma | chemotherapy | combined monoclonal antibody
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Outcomes of patients with double-hit lymphoma who achieve first complete remission
by Landsburg, Daniel J and Mato, Anthony R and Gerson, James N and Barta, Stefan K and Falkiewicz, Marissa K and Howlett, Christina and Feldman, Tatyana and Maly, Joseph and Blum, Kristie A and Hill, Brian T and Li, Shaoying and Medeiros, L. Jeffrey and Torka, Pallawi and Hernandez-Ilizaliturri, Francisco and Lue, Jennifer K and Amengual, Jennifer E and Reddy, Nishitha M and Singavi, Arun and Fenske, Timothy S and Chavez, Julio C and Kaplan, Jason B and Behdad, Amir and Petrich, Adam M and Peace, David J and Nathan, Sunita and Bast, Martin A and Vose, Julie M and Olszewski, Adam J and Costa, Cristiana and Lansigan, Frederick and Calzada, Oscar and Cohen, Jonathon B and Rivera, Xavier and Persky, Daniel O and Cassaday, Ryan D
Journal of clinical oncology, ISSN 0732-183X, 07/2017, Volume 35, Issue 20, pp. 2260 - 2267
Life Sciences & Biomedicine | Oncology | Science & Technology | Doxorubicin - therapeutic use | Recurrence | Cytarabine - therapeutic use | Humans | Lymphoma, B-Cell - therapy | Middle Aged | Male | Transplantation, Autologous | Methotrexate - therapeutic use | Lymphoma, B-Cell - genetics | Cyclophosphamide - therapeutic use | Stem Cell Transplantation | Female | Ifosfamide - therapeutic use | Etoposide - therapeutic use | Survival Rate | Remission Induction | Cytarabine - administration & dosage | Proto-Oncogene Proteins c-bcl-6 - genetics | Disease-Free Survival | Dexamethasone - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Methotrexate - administration & dosage | Proto-Oncogene Proteins c-myc - genetics | Proto-Oncogene Proteins c-bcl-2 - genetics | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Index Medicus | ORIGINAL REPORTS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Assessing Metabolic Changes in Response to mTOR Inhibition in a Mantle Cell Lymphoma Xenograft Model Using AcidoCEST MRI
by Akhenblit, Paul J and Hanke, Neale T and Gill, Alexander and Persky, Daniel O and Howison, Christine M and Pagel, Mark D and Baker, Amanda F
Molecular imaging, ISSN 1536-0121, 4/2016, Volume 15, p. 153601211664543
mTOR inhibition | extracellular pH | CEST MRI | therapy response | lymphoma | Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Radiology, Nuclear Medicine & Medical Imaging | Biochemical Research Methods | Science & Technology | Cell Survival - drug effects | Everolimus - pharmacology | TOR Serine-Threonine Kinases - metabolism | Acidosis - diagnostic imaging | Humans | Lymphoma, Mantle-Cell - drug therapy | Magnetic Resonance Imaging - methods | Molecular Imaging - methods | Everolimus - administration & dosage | Acidosis - metabolism | TOR Serine-Threonine Kinases - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | Tumor Burden - drug effects | Hydrogen-Ion Concentration - drug effects | Cell Line, Tumor | Lymphoma, Mantle-Cell - chemistry | Mice | Gene Expression Regulation, Neoplastic - drug effects | Lymphoma, Mantle-Cell - metabolism | TOR protein | Biotechnology | Statistical analysis | Growth rate | Xenotransplantation | AKT protein | Rapamycin | Malignancy | Kinases | pH effects | Lymphoma | 1-Phosphatidylinositol 3-kinase | Anticancer properties | Cell activation | Magnetic resonance imaging | Lymphocytes B | Mantle cell lymphoma | Xenografts | In vivo methods and tests | Mantle | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B‐cell lymphomas
by Qi, Wenqing and Liu, Xiaobing and Cooke, Laurence S and Persky, Daniel O and Miller, Thomas P and Squires, Matthew and Mahadevan, Daruka
International journal of cancer, ISSN 0020-7136, 06/2012, Volume 130, Issue 12, pp. 2997 - 3005
non‐Hodgkin lymphoma | mantle cell lymphoma | AT9283 | aurora kinase inhibitor | docetaxel | non-Hodgkin lymphoma | Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Taxoids - pharmacology | Apoptosis - drug effects | Humans | Lymphoma, Mantle-Cell - drug therapy | Aurora Kinases | Mice, SCID | Xenograft Model Antitumor Assays | Aurora Kinase B | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Urea - analogs & derivatives | Lymphoma, B-Cell - pathology | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cell Line, Tumor | Benzimidazoles - pharmacology | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Cell Cycle - drug effects | Urea - pharmacology | Lymphoma, B-Cell - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights